Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedizolid for Bone and Joint Infections
NCT03009045Phase 2Completed
- Sponsor
- The Lundquist Institute
- Start
- Feb 2017
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tedizolid in Bone and osteoarticular infections (BJI), sponsored by The Lundquist Institute. Started Feb 2017; status: completed.
02
Drugs
tedizolid
03
Conditions
Bone and osteoarticular infections (BJI)
Beyond the preview
Go deeper on NCT03009045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009045.